Clinical Trial Update: Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on patupilone for metastatic hormone-refractory prostate cancer, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-refractory Prostate Cancer

Drugs mentioned

• Patupilone (epothilone B)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Hormone Refractory Prostate Cancer | Phase 2 | Status: COMPLETED